Impact of the motor complications of Parkinson's disease on the quality of life

Mov Disord. 2005 Feb;20(2):224-30. doi: 10.1002/mds.20279.

Abstract

The impact of motor complications of Parkinson's disease (PD), especially levodopa-induced dyskinesias, on quality of life (QL) was studied in 143 patients with PD. All were evaluated on the Hoehn and Yahr (H&Y) scale, and the Motor part of the Unified Parkinson's Disease Rating Scale (UPDRS). Motor complications were analyzed using the UPDRS Parts IV(A) and IV(B) and the Abnormal Involuntary Movement Scale. A specific Parkinson's disease quality of life questionnaire (39-item version, PDQ-39) was used. Motor complications significantly worsened the PDQ-39 Summary Index (PDQ-SI) of patients with PD. The dimensions of Mobility, Activities of Daily Living, Stigma, and Communication were the most strongly affected. "Peak dose" dyskinesia decreased Mobility, Emotional Well-Being, and Cognition, whereas biphasic dyskinesia affected Mobility, Stigma, Communication, and Activities of Daily Living. Morning akinesia, end-of-dose fluctuations, and "unpredictable offs" decreased QL on the dimensions of Mobility, Activities of Daily Living, Stigma, and Communication. Nocturnal akinesia led to a deterioration of all dimensions of the PDQ-39. Thus, motor complications and especially nocturnal akinesia and biphasic dyskinesias worsened the QL of PD patients.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / adverse effects
  • Dyskinesia, Drug-Induced / physiopathology
  • Female
  • Follow-Up Studies
  • Health Status Indicators
  • Humans
  • Levodopa / adverse effects
  • Male
  • Middle Aged
  • Movement Disorders / etiology*
  • Movement Disorders / psychology
  • Neurologic Examination
  • Parkinson Disease / physiopathology*
  • Parkinson Disease / psychology*
  • Psychiatric Status Rating Scales
  • Quality of Life*
  • Retrospective Studies
  • Surveys and Questionnaires

Substances

  • Antiparkinson Agents
  • Levodopa